Paricalcitol
Paricalcitol, Zemplar (paricalcitol) is a small molecule pharmaceutical. Paricalcitol was first approved as Zemplar on 1998-04-17. It is used to treat hyperparathyroidism in the USA. The pharmaceutical is active against vitamin D3 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| endocrine system diseases | D004700 |
Trade Name
FDA
EMA
Paricalcitol, Zemplar (discontinued: Paricalcitol, Zemplar)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| paricalcitol | ANDA | 2024-08-12 |
| zemplar | New Drug Application | 2024-08-07 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hyperparathyroidism | EFO_0008506 | D006961 | E21.3 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
PARICALCITOL, ZEMPLAR, ABBVIE | |||
| 2023-10-18 | ODE*, ODE-125 | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2501 | Injection, paricalcitol, 1 mcg |
Clinical
Clinical Trials
119 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic renal insufficiency | D051436 | — | N18 | — | 8 | 17 | 14 | 15 | 53 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 9 | 18 | 9 | 18 | 53 |
| Secondary hyperparathyroidism | D006962 | EFO_1001173 | — | — | 4 | 7 | 20 | 15 | 46 |
| Hyperparathyroidism | D006961 | EFO_0008506 | E21.3 | — | 4 | 8 | 15 | 13 | 40 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 4 | 2 | 11 | 6 | 23 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 2 | 3 | 7 | 6 | 18 |
| Renal insufficiency | D051437 | — | N19 | — | — | 6 | 5 | 5 | 16 |
| Inflammation | D007249 | MP_0001845 | — | 1 | 2 | 1 | 3 | 2 | 9 |
| Renal dialysis | D006435 | EFO_0010690 | Z99.2 | — | 3 | 1 | 2 | 1 | 7 |
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | — | 2 | 2 | 1 | 5 |
Show 10 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Proteinuria | D011507 | — | R80 | — | — | 2 | — | 1 | 3 |
| Rickets | D012279 | EFO_0005583 | E55.0 | — | — | 2 | — | — | 2 |
| Left ventricular hypertrophy | D017379 | EFO_0003896 | — | — | — | 2 | — | — | 2 |
| Hypertrophy | D006984 | EFO_0002460 | — | — | — | 2 | — | — | 2 |
| Parathyroid diseases | D010279 | — | E21.5 | — | — | 1 | — | — | 1 |
| Gastric bypass | D015390 | EFO_0005244 | — | — | — | 1 | — | — | 1 |
| Coronary disease | D003327 | — | — | — | — | 1 | — | — | 1 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | 1 | — | — | 1 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 1 | — | — | 1 |
| Avitaminosis | D001361 | EFO_0005878 | E56.9 | — | — | 1 | — | — | 1 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 6 | 6 | — | — | — | 12 |
| Adenocarcinoma | D000230 | — | — | — | 3 | — | — | — | 3 |
| Pancreatic ductal carcinoma | D021441 | — | — | 1 | 2 | — | — | — | 3 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | 1 | 1 | — | — | — | 2 |
| Kidney transplantation | D016030 | — | — | — | 1 | — | — | 1 | 2 |
| Neoplasms | D009369 | — | C80 | 1 | 1 | — | — | — | 2 |
| Syndrome | D013577 | — | — | — | 1 | — | — | 1 | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | 1 | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | — | — | 1 | 2 |
| Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| Multiple myeloma | D009101 | — | C90.0 | 1 | — | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | 1 | — | — | — | — | 1 |
| Plasmacytoma | D010954 | — | C90.3 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
| Mucinous adenocarcinoma | D002288 | — | — | 1 | — | — | — | — | 1 |
| Rectal neoplasms | D012004 | — | — | 1 | — | — | — | — | 1 |
| Cystadenocarcinoma | D003536 | — | — | 1 | — | — | — | — | 1 |
| Pancreatitis | D010195 | EFO_0000278 | K85 | 1 | — | — | — | — | 1 |
| Chronic pancreatitis | D050500 | EFO_0000342 | K86.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fabry disease | D000795 | Orphanet_324 | E75.21 | — | — | — | — | 1 | 1 |
| Vascular calcification | D061205 | — | — | — | — | — | — | 1 | 1 |
| Pulmonary fibrosis | D011658 | — | J84.10 | — | — | — | — | 1 | 1 |
| Hereditary nephritis | D009394 | EFO_0004128 | Q87.81 | — | — | — | — | 1 | 1 |
| Hematuria | D006417 | — | R31 | — | — | — | — | 1 | 1 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Paricalcitol |
| INN | — |
| Description | Paricalcitol is a seco-cholestane and a hydroxy seco-steroid. It has a role as an antiparathyroid drug. It is functionally related to a vitamin D2. |
| Classification | Small molecule |
| Drug class | vitamin D analogs |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O |
Identifiers
| PDB | — |
| CAS-ID | 131918-61-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200622 |
| ChEBI ID | 7931 |
| PubChem CID | 5281104 |
| DrugBank | DB00910 |
| UNII ID | — |
Target
Agency Approved
VDR
VDR
Organism
Homo sapiens
Gene name
VDR
Gene synonyms
NR1I1
NCBI Gene ID
Protein name
vitamin D3 receptor
Protein synonyms
1,25-dihydroxyvitamin D3 receptor, Nuclear receptor subfamily 1 group I member 1, protein phosphatase 1, regulatory subunit 163, vitamin D (1,25- dihydroxyvitamin D3) receptor
Uniprot ID
Mouse ortholog
Vdr (22337)
vitamin D3 receptor (Q922X0)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Zemplar – AbbVie
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Paricalcitol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,201 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
12,693 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use